Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
O94906
UPID:
PRP6_HUMAN
Alternative names:
Androgen receptor N-terminal domain-transactivating protein 1; PRP6 homolog; U5 snRNP-associated 102 kDa protein
Alternative UPACC:
O94906; B2RAR5; B3KMC6; O95109; Q5VXS5; Q9H3Z1; Q9H4T9; Q9H4U8; Q9NTE6
Background:
Pre-mRNA-processing factor 6, also known as Androgen receptor N-terminal domain-transactivating protein 1, plays a crucial role in pre-mRNA splicing as part of the U4/U6-U5 tri-snRNP complex. This protein is essential for the assembly of the spliceosome, a complex responsible for removing introns from pre-mRNA. It also modulates the transactivation activity of AR and NR3C1, highlighting its significance in gene expression regulation.
Therapeutic significance:
Pre-mRNA-processing factor 6 is linked to Retinitis pigmentosa 60, a retinal dystrophy characterized by loss of vision and pigment deposits in the retina. Understanding the role of Pre-mRNA-processing factor 6 could open doors to potential therapeutic strategies for this debilitating condition.